COVID-19 Therapeutics Market Vendor and Technology Assessment Report 2024-2031

COVID-19 Therapeutics Market To Represent A Significant Expansion At 10.7% CAGR By 2030 | Global Industry Research Report, Size Estimation, Regional Growth, Key Company Profile

InsightAce Analytic Pvt. Ltd.'s recently published report, " COVID-19 Therapeutics Market- By Trends, Industry Competition Analysis, Clinical Trial/Pipeline Analysis, Revenue and Forecast Till 2030," includes a thorough analysis and study of the market, examining its key factors.

Get Free Access to Demo Report, Excel Pivot and ToC :https://www.insightaceanalytic.com/request-sample/1184

InsightAce Analytics' most recent market intelligence research estimates that the COVID-19 Therapeutics market will grow at a promising compound annual growth rate (CAGR) of 10.7% from 2021 to 2030, from a 2019 valuation of US$5.26 billion to US$25.6 billion.

The infectious disease COVID-19, which affects many people worldwide, is brought on by the most current corona virus exposure. The coronavirus can be treated with a variety of medication groups, including corticosteroids, antivirals, monoclonal antibodies, and kinase inhibitors. Therapeutics used to treat the new coronavirus are among the coronavirus therapy medications. Coronavirus can be treated with a variety of medication groups, including corticosteroids, antivirals, monoclonal antibodies, and kinase inhibitors. The World Health Organization (WHO) announced in August 2021 In an Effort to develop effective treatments for COVID-19, three novel candidate medications-artesunate, imatinib, and infliximab-are being examined in the most recent phase of worldwide Solidarity clinical trials. Additionally, other treatments have been authorized for emergency use by regulators worldwide. These include convalescent plasma, Roche's Actemra, Celltrion's plasma Regkirona,Roche GlaxoSmithKline/VirActemra Biotechnology's Xevudy's Regkirona (sotrovimab), Eli Lilly/ Vir and'sCompany's monoclonal antibodies bamlanivimab with etesevimab, Regeneron's casirivimab and imdevimab, and GlaxoSmithKline/Vir Biotechnology.

The global rise in COVID-19 prevalence is the main factor driving the growth of the COVID-19 therapeutics market. Growing public knowledge of the coronavirus and pharmaceutical companies' joint efforts to produce COVID-19 therapeutic medications are further factors driving the market.

Expert Knowledge, Just a Click Away:https://calendly.com/insightaceanalytic/30min?month=2024-02

Some of the key Players of COVID-19 Therapeutics market includes Atea Pharmaceuticals, Inc., CytoDyn, Celltrion, Eli Lilly and Company, NRX Pharmaceuticals, Shanghai Junshi Biosciences Co., Ltd., Veru Inc., Humanigen, Inc., Catalent, Inc., Cipla Limited, Molecular Partners AG, Merck, Novartis International AG, Regeneron Pharmaceuticals, Inc., Vir Biotechnology, Revive Therapeutics Ltd., Brii Biosciences Limited, GlaxoSmithKline plc, APEIRON Biologics AG, Bristol Myers Squibb, Janssen Pharmaceuticals, Trevena Inc, Ono Pharmaceutical Co., Ltd., Constant Therapeutics LLC, Amarin Corporation plc, FUJIFILM Toyama Chemical Co., Ltd., NeuroBo Pharmaceuticals, Inc., Innovation Pharmaceuticals Inc., Bellerophon Therapeutics, Sorrento Therapeutics, PhaseBio, Pfizer, Takeda, BioAegis Therapeutics, Roivant Sciences, A.I. Therapeutics, Inc., Celltex Therapeutics, Blade Therapeutics, Marinomed Biotech AG, Synairgen, SAb Biotherapeutics, Romark Laboratories, L.C., Kiniksa Pharmaceuticals, UNION therapeutics A/S, Fulcrum Therapeutics, and Other Prominent Players.

Key Developments:
• In Nov 2021, Pfizer Inc. announced its investigational novel COVID-19 oral antiviral candidate, PAXLOVID™, significantly reduced hospitalization and death, based on an interim analysis of the Phase 2/3 EPIC-HR (Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients) randomized, double-blind study of non-hospitalized adult patients with COVID-19, who are at high risk of progressing to severe illness.
• In Nov 2021, Merck and Ridgeback Biotherapeutics today announced that the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) has granted authorization in the United Kingdom (U.K.) for molnupiravir (MK-4482, EIDD-2801), the first oral antiviral medicine authorized for the treatment of mild-to-moderate COVID-19 in adults with a positive SARS-CoV-2 diagnostic test
• In Oct 2021, Regeneron Pharmaceuticals, Inc. Announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review a Biologics License Application (BLA) for REGEN-COV® (casirivimab and imdevimab) to treat COVID-19 in non-hospitalized patients and as prophylaxis in certain individuals. REGEN-COV is a combination of two monoclonal antibodies that was designed specifically to block infectivity of SARS-CoV-2, the virus that causes COVID-19, using Regeneron's proprietary VelocImmune® and VelociSuite® technologies
• In June 2021, Roche announced that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for intravenous Actemra/RoActemra® (tocilizumab) for the treatment of COVID-19 in hospitalised adults and pediatric patients (two years of age and older) who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO)
• In May 2021, GlaxoSmithKline plc and Vir Biotechnology, Inc. announced the U.S. Food and Drug Administration (FDA) granted an Emergency Use Authorization (EUA) for sotrovimab (previously VIR-7831), an investigational single-dose monoclonal antibody, for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients. Treatment with sotrovimab resulted in an 85% reduction in the risk of hospitalization or death in high-risk adult outpatients compared to placebo, based on interim results from Phase 3 COMET-ICE trial
• In May 2021, The U.S. Food and Drug Administration approved an emergency use authorization to the antibody treatment developed by Vir Biotechnology (VIR.O) and GlaxoSmithKline (GSK.L) for treating mild-to-moderate COVID-19 in people aged 12 years and older. Sotrovimab belongs to a class of drugs called monoclonal antibodies, which mimic natural antibodies that the body generates to fight off infection

Unlock Your GTM Strategy:https://www.insightaceanalytic.com/customisation/1184

Geographically, North America is expected to hold the largest share of R&D in the global market for COVID-19 therapeutics. This is due to several factors, including increased government spending on drug development, expanding government programs for COVID-19 vaccine R&D, a growing number of market participant, and the implementation of supportive government initiatives in the US and Canada. However, Because of the government's increased efforts to increase medicine manufacturing and the amount of research and development activities, the Asia Pacific area is anticipated to see substantial expansion in the target market. The Indian pharma regulator approved Eli Lilly and Company India's antibody medication combination for emergency use in June 2021. This medication is used to treat individuals with mild to moderate COVID-19. The monoclonal antibody medications bamlanivimab 700 mg and etesevimab 1400 mg have been approved by the company. Patients with mild to moderate COVID-19 are treated with both of these medications.

COVID-19 therapeutic Market Segments

COVID-19 therapeutic Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2030 based on Infection Type
• HCoV-229E
• HCoV-OC43
• SARS-CoV
• New Haven CoV
• HKU1-CoV
• MERS-CoV
• Other Infection Types

COVID-19 therapeutic Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2030 based on Drug Class
• Monoclonal Antibodies
• Antiviral
• Anticoagulant
• Glucocorticoid
• Nitric oxide
• Other Drug Class

COVID-19 therapeutic Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2030 based on Region
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa
North America COVID-19 Therapeutics market revenue (US$ Million) by Country, 2019 to 2030
• U.S.
• Canada
Europe COVID-19 Therapeutics market revenue (US$ Million) by Country, 2019 to 2030
• Germany
• France
• Italy
• Spain
• Russia
• Rest of Europe
Asia Pacific COVID-19 Therapeutics market revenue (US$ Million) by Country, 2019 to 2030
• India
• China
• Japan
• South Korea
• Australia & New Zealand
Latin America COVID-19 Therapeutics market revenue (US$ Million) by Country, 2019 to 2030
• Brazil
• Mexico
• Rest of Latin America

Middle East & Africa COVID-19 Therapeutics market revenue (US$ Million) by Country, 2019 to 2030
• GCC Countries
• South Africa
• Rest of Middle East & Africa

Why should buy this report:
 To receive a comprehensive analysis of the prospects for global COVID-19 Therapeutics market
 To receive industry overview and future trends of COVID-19 Therapeutics market
 To analyze the COVID-19 Therapeutics market drivers and challenges
 To get information on COVID-19 Therapeutics market size value (US$ Mn) forecast till 2030
 Major Investments, Mergers & Acquisition in COVID-19 Therapeutics market industry

Empower Your Decision-Making with 180 Pages Full Report @ https://www.insightaceanalytic.com/buy-report/1184

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.